Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
24.06
-1.54 (-6.02%)
Sep 11, 2026, 3:00 PM CST
SHA:688062 Revenue
Mabwell (Shanghai) Bioscience had revenue of 185.04M CNY in the quarter ending June 30, 2026, with 228.23% growth. This brings the company's revenue in the last twelve months to 873.99M, up 371.36% year-over-year. In the year 2025, Mabwell (Shanghai) Bioscience had annual revenue of 662.52M with 231.62% growth.
Revenue (ttm)
873.99M
Revenue Growth
+371.36%
P/S Ratio
11.90
Revenue / Employee
659.62K
Employees
1,325
Market Cap
10.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 662.52M | 462.73M | 231.62% |
| Dec 31, 2024 | 199.78M | 71.95M | 56.28% |
| Dec 31, 2023 | 127.84M | 100.11M | 361.03% |
| Dec 31, 2022 | 27.73M | 11.50M | 70.88% |
| Dec 31, 2021 | 16.23M | 10.92M | 206.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Nanjing Vazyme Biotech | 1.47B |
| Hualan Biological Vaccine | 1.19B |
| Sino Biological,Inc. | 768.00M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |